Surgical attenuation of spontaneous congenital portosystemic shunts in dogs resolves hepatic encephalopathy but not hypermanganesemia.

Hypermanganesemia is commonly recognized in human patients with hepatic insufficiency and portosystemic shunting. Since manganese is neurotoxic, increases in brain manganese concentrations have been implicated in the development of hepatic encephalopathy although a direct causative role has yet to be demonstrated. Evaluate manganese concentrations in dogs with a naturally occurring congenital shunt before and after attenuation as well as longitudinally following the changes in hepatic encephalopathy grade.

Mechanisms, causes, investigation and management of vomiting disorders in cats: a literature review.

Vomiting is a common presenting complaint in feline practice. This article differs from previous reviews in that it is an evidence-based review of the mechanisms, causes, investigation and management of vomiting in the domestic cat. Published evidence was reviewed, and then used to make recommendations for clinical assessment, diagnosis, antiemetic drug treatment, dietary management and monitoring of cats presenting with vomiting.

Oesophageal disease in 33 cats.

A retrospective study was performed to investigate the frequency of identification and characteristics of oesophageal disease in cats, including assessment of the utility of diagnostic techniques and clinical outcome. Thirty-three cats met the inclusion criteria, giving an in-clinic frequency of 33/2894 (approximately 1%) of feline referral cases. Vomiting and/or regurgitation were the most common presenting signs described, although a number of cats (6/33) showed neither.

Pulmonary oedema as a suspected adverse drug reaction following vincristine administration to a cat: a case report.

This report describes recurrent respiratory distress following vincristine administration to a cat with chronic lymphocytic leukaemia. The cat was treated with a combination of vincristine, chlorambucil and prednisolone with initial success. After approximately 4 months, dyspnoea developed within 6 h of vincristine administration.